Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Belgium

Marie Skłodowska-Curie Action · Running

4GETasthma Evicting pathogenic type-2 resident memory T cells from the lungs of asthmatics

Coordinator
Vib Vzw, Belgium
Runs
1 September 2026 to 31 August 2028
Status
Running
EU funding
€200k
Total cost
—
Partners
1 organisations in 1 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101211031

What the project is doing

In the project's own words, from its summary on CORDIS.

Asthma is the most common chronic lung disease. In most asthmatics, allergen-specific type-2 CD4 T cells orchestrate allergic airway inflammation by producing type-2 cytokines that ultimately drive asthma pathology. Studies suggest that a subset of long-lived memory Th2 cells that reside in the lung, known as tissue-resident memory Th2 cells (T2RM), play a significant role in driving asthma chronicity and persistence.

Therapies aimed at depleting T2RM from the lung represent a novel approach to treating asthma, however factors that regulate the generation and persistence of lung-T2RMs remain poorly understood. I hypothesize that distinct and druggable molecular pathways control lung-T2RM survival and re-activation. This work aims to decipher molecular and cellular mechanisms that regulate the maintenance and re-activation of T2RM within the asthmatic lung niche.

The host lab has recently developed a novel TCR transgenic (Tg) mouse line (1DER-CD5), containing a monoclonal population of house dust mite (HDM) specific CD4 T cells with high T2RM differentiation potential, which has been confirmed in preliminary experiments performed since joining the host lab. In WP1, I will perform single cell transcriptomic and proteomic analysis on 1DER-CD5 T cells in the lungs of mice in the memory phases of HDM-induced asthma to predict molecular and cellular networks that regulate lung-T2RM.

In WP2, I will utilize targeted spatial transcriptomics, paired with confocal microscopy, to define the lung-T2RM niche and validate molecular and cellular interactions predicted in WP1. In WP3, I will use an in vivo CRISPR-screening approach with Cas9+ 1DER-CD5 T cells to pinpoint key druggable pathways that regulate lung-T2RM survival and re-activation. This work is expected to identify molecular pathways critical in regulating the persistence and re-activation of lung-T2RM, potentially leading to the development of novel therapies to deplete pathogenic T2RM from the airways of asthmatics.

Topics

Who is involved

OrganisationCityCountryRole
Vib VzwZwijnaarde - GentBelgiumCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI